Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Carasent AB (publ) is a health tech group specializing in cloud-based electronic health record (EHR) systems and platform services for the healthcare sector across the Nordics and Germany. Founded in 1997 and headquartered in Gothenburg, Sweden, the company develops mission-critical software solutions, including Webdoc, Webdoc X, Metodika, Ad Curis, Ad Opus, Data-AL, Medrave, Vårdrummet, Ad Voca, and HPI Plustoo, alongside an ecosystem for patient communication and business intelligence. With approximately 196-199 employees led by CEO Daniel Ohman, Carasent focuses on minimizing administrative burdens, enhancing data access, and enabling insights to improve care quality and efficiency. Its decentralized structure ensures deep market understanding and expertise in healthcare, rehabilitation, and occupational health segments, fostering synergies across ecosystems. Committed to sustainability, Carasent achieved ISO 14001 certification in 2024, promoting environmentally responsible practices among partners and clients. Operating in the health information services industry, it plays a vital role in digital transformation by supporting providers in preventing illness and delivering high-quality care.
kr 2.04
+kr 0.05 (+2.36%)
EOD Jun 23, 2026 · Twelve Data
Operating margin is thin at 2.74%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 24.9% YoY with margins expanding 20.7pp.
Negative free cash flow of -kr 476K. The business is consuming cash, not generating it.
3.5x earnings, 4.0x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 349M
▲ +24.9% YoY
Net Income (TTM)
kr 41M
▲ +182.0% YoY
Op. Margin
3.69%
▲ +20.7pp YoY
ROIC
1.06%
▲ +5.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 37M
▲ +90.8% YoY
Op. Cash Flow (TTM)
kr 81M
▲ +46.7% YoY
Net Debt
-kr 106M
Net Cash Position
Cash & Equiv.
kr 138M
3Y CAGR: +20.8%
Continue Research
At a P/E of 3.5 and a price-to-free-cash-flow of 4.0, Carasent AB (publ) (CARA.XSTO) trades below a two-stage DCF intrinsic value of about SEK 14.05 per share, so at SEK 2.04 the stock looks undervalued (590.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Carasent AB (publ) scores 84/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 14.05 per share for CARA.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 10.53. At today's SEK 2.04, that puts the stock about 590.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Carasent AB (publ) scores 84 out of 100 on Intrinsiqq's quality score, passing 6 of 7 checks, which makes it a high-quality business on these measures. Recent fundamentals include a 3.7% operating margin and a 1.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CARA.XSTO currently trades below its estimated intrinsic value and scores 84/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.